Analysts Offer Predictions for Opko Health Inc.’s Q3 2016 Earnings (OPK)
Opko Health Inc. (NYSE:OPK) – Stock analysts at Oppenheimer Holdings issued their Q3 2016 earnings per share (EPS) estimates for shares of Opko Health in a note issued to investors on Sunday. Oppenheimer Holdings analyst M. Ho forecasts that the firm will post earnings per share of ($0.01) for the quarter. Oppenheimer Holdings has a “Hold” rating on the stock. Oppenheimer Holdings also issued estimates for Opko Health’s Q4 2016 earnings at ($0.02) EPS, FY2016 earnings at ($0.03) EPS, FY2017 earnings at $0.03 EPS, FY2018 earnings at $0.61 EPS, FY2019 earnings at $1.17 EPS and FY2020 earnings at $1.85 EPS.
A number of other analysts also recently issued reports on the company. Jefferies Group reaffirmed a “hold” rating and issued a $10.00 target price on shares of Opko Health in a research note on Monday. JPMorgan Chase & Co. set a $14.00 price objective on Opko Health and gave the stock a “buy” rating in a research report on Tuesday, August 9th. Zacks Investment Research raised Opko Health from a “sell” rating to a “hold” rating in a research report on Tuesday, July 12th. Standpoint Research raised their price objective on Opko Health from $16.00 to $18.00 and gave the stock a “buy” rating in a research report on Tuesday, June 21st. Finally, Deutsche Bank AG cut their price objective on Opko Health from $11.00 to $10.00 and set a “hold” rating for the company in a research report on Thursday, June 16th. Five investment analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company’s stock. Opko Health presently has an average rating of “Buy” and an average price target of $13.20.
Opko Health (NYSE:OPK) opened at 9.56 on Wednesday. Opko Health has a one year low of $7.12 and a one year high of $11.85. The company has a market capitalization of $5.26 billion and a P/E ratio of 40.00. The firm has a 50-day moving average of $10.07 and a 200-day moving average of $10.08.
Opko Health (NYSE:OPK) last announced its earnings results on Monday, August 8th. The company reported $0.02 EPS for the quarter, topping the Zacks’ consensus estimate of ($0.03) by $0.05. The firm earned $357.10 million during the quarter, compared to the consensus estimate of $324.11 million. The business’s revenue for the quarter was up 742.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.09) earnings per share.
Several institutional investors have recently made changes to their positions in OPK. Bridger Management LLC bought a new position in shares of Opko Health during the first quarter valued at about $13,863,000. Amici Capital LLC acquired a new stake in Opko Health during the first quarter valued at $842,000. Schonfeld Strategic Advisors LLC acquired a new stake in Opko Health during the first quarter valued at $141,000. LGL Partners LLC acquired a new stake in Opko Health during the first quarter valued at $556,000. Finally, Geode Capital Management LLC boosted its stake in Opko Health by 6.6% in the first quarter. Geode Capital Management LLC now owns 1,923,455 shares of the company’s stock valued at $19,984,000 after buying an additional 118,512 shares during the last quarter.
In related news, CEO Phillip Md Et Al Frost acquired 48,400 shares of the firm’s stock in a transaction dated Thursday, August 25th. The stock was acquired at an average price of $9.06 per share, for a total transaction of $438,504.00. Following the purchase, the chief executive officer now owns 3,068,951 shares of the company’s stock, valued at approximately $27,804,696.06. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.
About Opko Health
OPKO Health, Inc (OPKO) is a healthcare company. The Company operates through two segments: diagnostics and pharmaceutical. The pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, and its pharmaceutical research and development operations. The diagnostics segment primarily consists of its clinical laboratory operations.
Receive News & Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.